Mankind Pharma Collaborates With Russian RDIF For Distribution Of Sputnik V In India

Delhi based Mankind pharma has collaborated with Russian Direct Investment Fund (RDIF), Russia’s sovereign wealth fund for sales and distribution of Sputnik V in India, sources told ET.“The co-operation agreement has been signed for sales and distribution of much anticipated Covid-19 vaccine Sputnik V with RDIF by Mankind pharma,” sources said without divulging much details on the agreement.The announcement to this effect is likely to be made by next week, sources further said.RDIF has reached agreements with Indian manufacturers to produce 300 million doses of the shot, sources said. Earlier in September, Dr. Reddy’s and RDIF entered into a partnership to conduct clinical trials of Sputnik V vaccine and its distribution in India. As part of the partnership, RDIF shall supply 100 million doses of the vaccine to Dr. Reddy’s upon regulatory approval in India.Dr Reddy’s received approval from the Drug Control General of India (DCGI) on Saturday to conduct clinical trials for Sputnik V in India. This will be a multicenter and randomized controlled study, which will include safety and immunogenicity study.While Dr Reddy’s and RDIF initially planned to conduct Phase 3 trials of the vaccine, but the subject expert committee (SEC) of the Central Drugs Standards Control Organization (CDSCO) which is looking into Covid related proposals askedDr Reddy’s to conduct a Phase 2 and 3 clinical trial in India, instead of just a phase 3 study.

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!